Results 11 to 20 of about 8,921 (227)
After more than sixty years we are still unclear whether LSD has a place in clinical psychiatry
Research in Psychotherapy, 2020 Dear Editor, The use of the psychedelic Lysergic Acid Diethylamide (LSD) has again provoked scientific debate over its efficacy and safety. In the 1950s-1960s LSD was used in psychotherapy for treating depression, anxiety related to terminal cancer ...
arthur saniotis
doaj +1 more source
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Cell Reports, 2023 Summary: Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled
Vern Lewis +18 more
doaj +1 more source
Pharmaceuticals, 2021 Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD ...
Gniewko Więckiewicz +4 more
doaj +1 more source
Biological studies of clavine alkaloids targeting CNS receptors
Frontiers in Psychiatry, 2023 In contrast to well established psychedelics such as lysergic acid diethylamide (LSD) and psilocybin, ergot alkaloids of the clavine subclass have not been thoroughly investigated, in spite of their broad occurrence in nature and their well-established ...
Nikhil R. Tasker +2 more
doaj +1 more source
eLife, 2021 Psychoactive drugs can transiently perturb brain physiology while preserving brain structure. The role of physiological state in shaping neural function can therefore be investigated through neuroimaging of pharmacologically induced effects.
Joshua B Burt +7 more
doaj +1 more source
South African Medical Journal, 2023 Healthcare providers face the challenging task of managing patients who suffer from chronic nociplastic pain conditions. Pain is a multidimensional experience, and the current approach to managing people in chronic pain often fails to meet the needs
J Van Der Walt, R Parker
doaj +1 more source
Separations, 2023 Lysergic acid diethylamide (LSD) is a powerful hallucinogen. Its detection is limited by its low dosage; moreover, LSD is rapidly metabolized into 2-oxo-3-hydroxy-LSD (O-H-LSD).
Alexandra Dimitrova +5 more
doaj +1 more source
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Frontiers in Synaptic Neuroscience, 2020 Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD ...
Simon Andrew Vann Jones +1 more
doaj +1 more source
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775) [PDF]
, 2018 Lysergic acid diethylamide (LSD) is perhaps one of the best-known psychoactive substances and many structural modifications of this prototypical lysergamide have been investigated. Several lysergamides were recently encountered as “research chemicals” or
Abramson +67 more
core +1 more source
Acute effects of lysergic acid diethylamide (LSD) on resting brain function
Swiss Medical Weekly, 2019 Lysergic acid diethylamide (LSD) is a potent hallucinogenic substance that was extensively investigated by psychiatrists during the 1950s and 1960s.
Felix Müller, Stefan Borgwardt
doaj +1 more source